AN2 Therapeutics (ANTX) Retained Earnings (2021 - 2026)
AN2 Therapeutics' (ANTX) quarterly Retained Earnings came in at -$5000.0 in Q1 2026, down 110.42% year-on-year from $48000.0 in Q1 2025, and up 100.0% on a QoQ basis from -$241.0 million in Q4 2025.
AN2 Therapeutics (ANTX) Retained Earnings (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Retained Earnings data on file, last reported at -$5000.0 in Q1 2026.
- On a quarterly basis, Retained Earnings fell 110.42% year-over-year to -$5000.0 in Q1 2026; TTM through Mar 2026 was -$5000.0, a 110.42% decrease from a year earlier, with the FY2025 full-year figure at -$241.0 million, down 17.09% from the prior year.
- Retained Earnings for Q1 2026 stood at -$5000.0, up from -$241.0 million in the prior quarter.
- Over the last five years, Retained Earnings for ANTX reached as high as $291.7 million in Q2 2025 and fell as low as -$241.0 million in Q4 2025.
- Historically, Retained Earnings has averaged $33.4 million across 5 years, with a median of -$27000.0 in 2024.
- Across the five-year window, Retained Earnings slumped 1285.19% in 2022 and surged 1080485.19% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$374000.0 in 2022, then surged by 74667.11% to $278.9 million in 2023, then plunged by 173.79% to -$205.8 million in 2024, then dropped by 17.09% to -$241.0 million in 2025, then surged by 100.0% to -$5000.0 in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$5000.0 in Q1 2026, -$241.0 million in Q4 2025, and -$232.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | AN2 Therapeutics | 167.57 Mn | 167.57 Mn | - | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | -240.95 Mn |
| Sep 30, 2025 | -232.24 Mn |
| Jun 30, 2025 | 291.70 Mn |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | -205.78 Mn |
| Sep 30, 2024 | 285.81 Mn |
| Jun 30, 2024 | -27,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | 278.88 Mn |
| Sep 30, 2023 | -122,000.00 |
| Jun 30, 2023 | 208.73 Mn |
| Mar 31, 2023 | -175,000.00 |
| Dec 31, 2022 | -374,000.00 |
| Sep 30, 2022 | -541,000.00 |
| Jun 30, 2022 | 182.77 Mn |
| Mar 31, 2022 | -158,000.00 |
| Dec 31, 2021 | -27,000.00 |